Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o1/07/96 \ \ Origin: Appendix 5 \ \ Amended o1/07/98, o1/09/99, o1/07/00, 30/09/01, 11/03/02, o1/01/03, 24/10/05, o1/08/12, o4/03/13$

Name of entity	
Somnomed Limited	
ADM	
ABN	_
35 003 255 221	

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

¹ +Class of *securities issued or to be issued

Fully paid ordinary

Number of *securities issued or to be issued (if known) or maximum number which may be issued 1,613,983 fully paid ordinary shares to be issued under the institutional component of a 2 for 25 pro-rata non-renounceable Entitlement Offer

Principal terms of the 3 +securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; +convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares under the institutional component of the Entitlement Offer and ranking equally with all other fully paid ordinary shares

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$2.50
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The proceeds of the Entitlement Offer will be used to provide working capital for the Company and any capital investment associated with the Company's Direct To Patient business.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
	resolution under rule 7.1A was passed Number of *securities issued without security holder approval	

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	⁺ Issue dates	16 May 2016	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	Number 55,098,638 (post Institutional Entitlement Offer)	⁺ Class Fully Paid Ordinary Shares.

⁺ See chapter 19 for defined terms.

Number and +class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

share
share
share
share
5

Dividend policy (in the case of a 10 trust, distribution policy) on the increased capital (interests)

Same as policy on all fully paid ordinary shares.

Part 2 - Pro rata issue

11	Is	security	holder	approval
	rec	uired?		

No

12 Is the issue renounceable or nonrenounceable?

Non-renounceable

Ratio in which the *securities 13 will be offered

2 New Shares for Every 25 Existing Shares

⁺Class of ⁺securities to which the 14 offer relates

Fully paid ordinary shares

⁺Record date to determine 15 entitlements

7.00pm (EST) 5 May 2016

Will holdings different 16 on registers (or subregisters) be aggregated calculating for entitlements?

No

Policy for deciding entitlements 17 in relation to fractions

Entitlements are rounded up

18 Names of countries in which the entity has security holders who will not be sent new offer documents

China, Germany, France, United Kingdom, Ireland, Netherlands Sweden, United States of America,

Japan, Sri Lanka

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

19	Closing date for receipt of acceptances or renunciations	4 May 2016
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the sissue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A

⁺ See chapter 19 for defined terms.

31			N/A	
32	of the	do security holders dispose eir entitlements (except by nrough a broker)?	N/A	
33	⁺ Issue	e date	16 May 2016	
	ed only o	of ⁺ securities	S oplying for quotation of securities	
(a)	(tick o	+Securities described in Part	1	
(b)		All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entiti	es tha	t have ticked box 34(a)		
Addi	tional	securities forming a new	class of securities	
Tick to docum		e you are providing the informat	ion or	
35			securities, the names of the 20 largest holders of the the number and percentage of additional *securities	
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 100,000 10,001 - 100,000 100,001 and over		
37		A copy of any trust deed for	the additional *securities	

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

Entitie	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)	N/A	
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number N/A	+Class N/A

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 13 May 2016

Company Secretary

Print name: Terry Flitcroft

== == == ==

+ See chapter 19 for defined terms.

Appendix 3B Page 8 04/03/2013

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	50,935,600	
 Add the following: Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 		
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Subtract the number of fully paid +ordinary 		
securities cancelled during that 12 month period		
"A"	50,935,600	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
Multiply "A" by 0.15	7,640,340
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.
 Insert number of †equity securities issued or agreed to be issued in that 12 month period not counting those issued: Under an exception in rule 7.2 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	150,473 shares - 31/7/15 838,000 shares - 13/10/15 310,000 shares - 30/10/15 40,000 shares - 6/11/15 12,454 shares - 14/1/16 50,159 shares - 28/4/16 400,000 options - 3/5/16
"C"	Total of 1,801,086 equity securities
Step 4: Subtract "C" from ["A" x "L placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15 Note: number must be same as shown in Step 2	7,640,340
Subtract "C"	(1,801,086)
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	5,839,254
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in Step 1 of Part 1	N/A	
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
 Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	N/A	
"E"	N/A	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10 Note: number must be same as shown in Step 2	N/A	
Subtract "E" Note: number must be same as shown in Step 3	N/A	
<i>Total</i> ["A" x 0.10] – "E"	N/A Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.